» Articles » PMID: 20525701

Stepwise Radical Endoscopic Resection for Eradication of Barrett's Oesophagus with Early Neoplasia in a Cohort of 169 Patients

Overview
Journal Gut
Specialty Gastroenterology
Date 2010 Jun 8
PMID 20525701
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Endoscopic resection is safe and effective to remove early neoplasia (ie,high-grade intra-epithelial neoplasia/early cancer) in Barrett's oesophagus. To prevent metachronous lesions during follow-up, the remaining Barrett's oesophagus can be removed by stepwise radical endoscopic resection (SRER). The aim was to evaluate the combined experience in four tertiary referral centres with SRER to eradicate Barrett's oesophagus with early neoplasia.

Methods:

Design: Retrospective cohort study.

Setting: Four tertiary referral centres.

Participants: 169 patients (151 males, age 64 years (IQR 57-71), Barrett's oesophagus 3 cm (IQR 2-5)) with early neoplasia in Barrett's oesophagus < or = 5 cm, without deep submucosal infiltration or lymph node metastases, treated by SRER between January 2000 and September 2006.

Intervention: Endoscopic resection every 4-8 weeks, until complete endoscopic and histological eradication of Barrett's oesophagus and neoplasia.

Results: According to intention-to-treat analysis complete eradication of all neoplasia and all intestinal metaplasia by the end of the treatment phase was reached in 97.6% (165/169) and 85.2% (144/169) of patients, respectively. One patient had progression of neoplasia during treatment and died of metastasised adenocarcinoma (0.6%). After median follow-up of 32 months (IQR 19-49), complete eradication of neoplasia and intestinal metaplasia was sustained in 95.3% (161/169) and 80.5% (136/169) of patients, respectively. Acute, severe complications occurred in 1.2% of patients, and 49.7% of patients developed symptomatic stenosis.

Conclusions: SRER of Barrett's oesophagus < or = 5 cm containing early neoplasia appears to be an effective treatment modality with a low rate of recurrent lesions during follow-up. The procedure, however, is technically demanding and is associated with oesophageal stenosis in half of the patients.

Citing Articles

Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus.

Porschen R, Fischbach W, Gockel I, Hollerbach S, Holscher A, Jansen P United European Gastroenterol J. 2024; 12(3):399-411.

PMID: 38284661 PMC: 11017771. DOI: 10.1002/ueg2.12523.


Endoscopic therapy replaces surgery for clinical T1 oesophageal cancer in the Netherlands: a nationwide population-based study.

Noordzij I, Hazen M, Nieuwenhuijzen G, Verhoeven R, Schoon E Surg Endosc. 2023; 37(6):4535-4544.

PMID: 36849563 PMC: 10234922. DOI: 10.1007/s00464-023-09914-x.


Today's Mistakes and Tomorrow's Wisdom in Endoscopic Treatment and Follow-Up of Barrett's Esophagus.

Barret M Visc Med. 2022; 38(3):189-195.

PMID: 35814978 PMC: 9210024. DOI: 10.1159/000522512.


Stepwise endoscopic submucosal dissection for circumferential Barrett's esophageal dysplasia and carcinoma: a case series.

Tanaka I, Hirasawa D, Saito H, Akahira J, Fujishima F, Matsuda T Endosc Int Open. 2022; 10(2):E215-E221.

PMID: 35178340 PMC: 8847047. DOI: 10.1055/a-1672-4122.


Benefit of radiofrequency ablation after widespread endoscopic resection of neoplastic Barrett's esophagus in daily practice.

Godat S, Marx M, Caillol F, Robert M, Autret A, Bories E Ann Gastroenterol. 2022; 35(1):34-41.

PMID: 34987286 PMC: 8713341. DOI: 10.20524/aog.2021.0685.